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Abstract. Global changes in dietary habits in the last decades 
caused an increase of added sugar consumption all over the world, 
which has been linked to the increasing prevalence of obesity, 
dyslipidemia, insulin resistance and cardiovascular disease. Fructose 
is widely used as a sweetener in the food and beverage industry, 
either as an integrant of the sucrose molecule or as a component of 
high fructose corn syrups. The consumption of fructose in beverages 
is especially dangerous, as the process of energy compensation by 
reduction in the ingestion of other foods does not work equally well 
with liquid than solid foods. Besides, fructose is the carbohydrate 
with the highest ability to induce hypertriglyceridemia, due to a 
marked increase in lipogenesis compared with glucose. In this 
review we will discuss some of the most recent studies performed in 
animal models and in humans to investigate the effects of excessive 
fructose consumption. 
 
Correspondence/Reprint request: Dr. Núria Roglans, Department of Pharmacology and Therapeutic Chemistry, 
School of Pharmacy, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona. E-mail: roglans@ub.edu 
Miguel Baena et al. 2 
Introduction 
   
 Fructose is a natural sugar contained in fruits and honey, and in this 
form it constitutes a component of a healthy, well-balanced diet. Fructose 
is also used to sweeten foods and beverages during processing or 
preparation, and then we refer to fructose as an “added sugar”. Usually, 
fructose is added to foodstuffs as sucrose (table sugar, a disaccharide 
composed of glucose and fructose) or as high fructose corn syrup (HFCS, a 
mixture of fructose and glucose at variable proportions, typically 55% 
fructose/45% glucose). Global changes in dietary habits in the last decades 
caused an increase of added sugar consumption all over the world, but 
especially in industrialized countries. As an example, US dietary data show 
that between 1977 and 1994 the average daily consumption of added 
sugars increased by 35% [1]. Although these data refer to all caloric 
sweeteners added to food or drinks, added sugars are considered a 
surrogate for fructose consumption [2]. The increase in the consumption of 
added sugars has been linked to several health disturbances, such as 
obesity, dyslipidemia, insulin resistance and cardiovascular disease [3-6]. 
Recognizing these deleterious effects to human health, several dietary 
guidelines from different countries provided recommendations to moderate 
the intake of added sugars, and possibly as a result of these policies, their 
consumption has decreased since 1999 [7]. However, sugar consumption is 
still excessive according to the American Heart Association latest 
recommendations, which fixed an upper limit of intake for added sugars of 
100-150 calories per day [8]. Consistent with this, research on the 
metabolic effects of the main added sugar, fructose, and the molecular 
mechanisms involved is warranted. In previous articles we revised 
scientific evidences, from both animal and human studies, linking fructose 
consumption to metabolic disturbances, up to 2011 [9,10]. In the present 
review, we will focus on articles published during 2012 and 2013, as well 
as on our own results, obtained using liquid fructose-supplemented rats 
and mice as experimental models. We will also review some of the most 
recent studies investigating the effects of high fructose consumption in 
humans. 
 
1. Studies in animal models  
 
 Fructose administration to laboratory animals (most commonly rodents) 
induces metabolic derangements in several tissues -namely liver, adipose 
tissue, heart and skeletal muscle- so these animals can be used as models to 
decipher the molecular mechanisms involved in these alterations. 
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1.1. Fructose effects in the liver 
 
1.1.1. Fructose, fatty liver and mechanisms involved 
  
 In an earlier study [11] we demonstrated that fructose administration to 
male rats (10% w/v in drinking water for 14 days) causes 
hypertriglycerideamia and hepatic steatosis due the conjunction of two 
metabolic alterations, an increase in liver lipogenesis and a decrease in 
hepatic fatty acid oxidation. The latter is a pathway that catalyzes the 
catabolism of fatty acids after they are activated to their acyl-CoA forms by 
the enzyme acyl CoA synthase (ACS). Recently, Dong et al [12] investigated 
the role of long chain ACS (ACSL) in hamsters fed a diet containing 60% of 
fructose for 28 days. Their results showed that the fructose diet specifically 
reduced ACSL through liver X receptor (LXR) and retinoid X receptor 
(RXR) signaling, opening the possibility that LXR agonists, by increasing 
hepatic ACSL expression, could reduce fructose-induced hepatic steatosis.  
 Creszenzo et al. also found an increase in hepatic de novo lipogenesis in 
male Sprague Dawley rats fed a fructose-rich diet (30% fructose in solid 
form) for 8 weeks [13]. The most interesting finding of this study was 
increased hepatic mitochondrial mass in fructose-fed rats. The authors 
hypothesize that this would increase the flux of substrates through pyruvate 
carboxylase and pyruvate dehydrogenase, generating substrates for 
gluconeogenesis. Increased hepatic gluconeogenesis is one of the classic 
features of insulin resistance, and in fact we observed a rise in the liver 
glucose output after a bolus administration of a direct gluconeogenic 
precursor, such as pyruvate, to 14-day fructose-supplemented rats [14]. 
However, we were surprised to notice a significant reduction in the 
expression of two key gluconeogenic enzymes, phosphoenol pyruvate 
carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pc), despite a clear 
impairment in insulin signaling in the livers of these rats. Creszenzo et al 
proposed that an increase in the expression of enzymes controlling the 
substrate flux from cytosolic pyruvate to glucose formation could explain 
enhanced hepatic gluconeogenesis [13]. In fact, we observed an increase in 
the hepatic expression of the enzymes malate dehydrogenase and malic 
enzyme in 14-day fructose-supplemented rats, which could explain the 
increased liver output of glucose in the pyruvate tolerance test, despite the 
reduced expression of both G6Pc and PEPCK [14]. 
 Several studies analyzed how fructokinase, the first enzyme in the 
hepatic metabolism of fructose, contributes to the deposition of fat in the 
liver. Ishimoto et al. [15] demonstrated that mice lacking both fructokinase 
isoforms (A and C) were protected from the fructose-induced features of 
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metabolic syndrome (including hepatic steatosis) observed in wild type 
mice. Moreover, these effects were exacerbated in mice lacking fructokinase 
A, suggesting that this isoform protects against fructokinase C-mediated 
metabolic syndrome.  
 Lanaspa et al [16] used fructokinase knockout mice to evaluate the 
effects of glucose supplementation (10% w/v in drinking water). Glucose 
feeding induced fatty liver in wild type but not in fructokinase-deficient 
animals, showing that this effect was almost entirely mediated by 
fructokinase. However, fructokinase does not metabolize glucose, therefore 
the protective effect was attributed to the fact that a significant proportion of 
the ingested glucose was converted into fructose in the liver. Metabolism of 
this endogenous fructose is blocked in fructokinase-deficient mice, 
protecting against fatty liver. More recently, the same research group studied 
whether fructokinase had also a role in fatty liver induction through a high 
fat-high sucrose diet (HFHSD) [17]. They observed that wild type mice fed a 
HFHSD developed more severe hepatic steatosis compared to mice fed a 
high fat diet. Moreover HFHSD-fed wild type mice showed hepatic 
inflammation and collagen deposition in the liver, while the development of 
steatosis from a high fat diet alone did not induce inflammation or fibrosis. 
Importantly, fructokinase knockout mice fed a HFHSD were completely 
protected from the development of hepatic inflammation and fibrosis despite 
similar energy intake compared to wild type mice.  
  
1.1.2. Fructose and hepatic insulin resistance 
 
 In animal models, fructose feeding (especially at high percentages in 
solid form) induces hepatic insulin resistance. We also observed insulin 
resistance in female, but not male rats, supplemented with 10% fructose in 
liquid form for 2 weeks [9]. Our preliminary results, after 8 weeks of 
supplementation in female rats, show hyperinsulinemia and a clear reduction 
in the expression of insulin receptor substrate (IRS)-2, a major transducer of 
insulin signaling in the liver (Figure 1). However, plasma glucose levels and 
ISI were not altered, suggesting that in these animals increased insulin 
suffices to control plasma glucose levels, masking the underlying insulin 
resistance (unpublished results). We also observed that mice fed a high fat 
(western) diet plus 15% liquid fructose (W+F) consumed an equivalent 
amount of calories compared to mice fed the western diet alone without 
fructose (W), but only the W+F group exhibited hyperinsulinemia and a 
reduction in the insulin sensitivity index (ISI) compared to mice fed normal 
chow [18]. This is in line with the reduced Akt phosphorylation seen only in 
the W+F group, and points out to a specific effect of fructose, only when it is 
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given in combination with a high fat diet, on hepatic insulin signaling in 
mice [18]. 
 We reported previously that carbohydrate response element binding 
protein (ChREBP) is the main responsible for the increase in hepatic 
lipogenesis following fructose supplementation in rats [11, 19-21]. Recently, 
Erion et al studied whether ChREBP is also related to fructose-induced insulin 
resistance [22]. To this end, they administered a ChREBP specific antisense 
oligonucleotide to male Sprague-Dawley rats fed a high-fructose diet             
(60% fructose in solid form). As expected, knockdown of ChREBP led to a 
decrease in the expression of genes controlled by this transcription factor 
(lipogenic genes such as ACC, FAS and SCD-1). ChREBP knockdown caused 
a tendency towards decreased de novo lipogenesis, but these changes did not 
correlate with a decrease in hepatic triglyceride, and therefore were not 
associated with improvements in hepatic insulin sensitivity. 
 
1.1.3. Endoplasmic reticulum stress, autophagy and inflammation 
 
 It has been suggested that endoplasmic reticulum (ER) stress may play a 
role in the development of hepatic insulin resistance under conditions of 
elevated de novo lipogenesis, as occurs with increased fructose consumption. 
ER stress is characterized by the activation of the unfolded protein response 
(UPR) signaling, that reduce temporarily the flow of proteins that reach the 
ER. The UPR is initiated by three transmembrane proteins: IRE1               
(inositol-requiring enzyme 1), PERK (protein kinase-like reticulum kinase) 
and ATF-6 (activating transcription factor-6). A recent study in mice fed a 
high fat diet (60% from saturated fat) or a high fructose diet (35% fructose in 
solid form), showed that both diets caused liver steatosis and hepatic insulin 
resistance, but only the high fructose diet increased de novo lipogenesis, and 
this effect was coupled with activation of the IRE1 and PERK patways [23]. 
The same research group demonstrated recently that treatment of the 
fructose-fed mice with fenofibrate, a PPARα agonist, eliminated               
fructose-induced hepatic steatosis and insulin resistance while causing an 
activation of the IRE1 and PERK branches of the UPR [24]. 
 We also studied the effects of fructose feeding (10% w/v in drinking 
water for 8 weeks) in female Sprague Dawley rats on ER stress pathways 
[25]. Neither PERK nor ATF-6 branches were affected by fructose, while 
there was a marked increase in IRE1 phosphorylation, indicative of 
activation. This is in accordance with our previous results in female rats 
supplemented with fructose for 2 weeks [9]. However, while in 2-weeks 
supplemented rats the increase in IRE1 phosphorylation correlated with an 
increase in the spliced form of X-box-binding protein (XBP)-1 mRNA and 
nuclear protein [9], this effect is not apparent after 8 weeks of treatment 
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(Figure 1), suggesting that ER stress is somehow compensated in these 
animals. It remains to be determined whether longer treatments with fructose 
maintain or rather exacerbate the ER stress response.  
 Due to the involvement of ER stress in the metabolic alterations caused 
by fructose feeding, Ren et al studied the effects of an ER stress inhibitor  
(4-phenylbutyric acid, PBA) on rats fed a high fructose diet [26]. The 
authors showed that treatment with PBA significantly reduced hepatic ER 
stress and improved liver steatosis induced by high-fructose feeding.  
 Insulin resistance has also been associated to a state of chronic low-
grade inflammation derived from the activation of the inflammasome [27]. 
The inflammasommes are large multimolecular complexes that upon 
activation by various stimuli result in the processing and maturation of the 
precursors of the inflammatory cytokines interleukin (IL)-1  and IL-18, via 
caspase-1. A significant increase in renal nucleotide-binding domain and 
leucine-rich repeat protein 3 (NLRP3) inflammasome has been recently 
shown in rats fed fructose [28] or high fructose corn syrup [29]. However, it 
is not known whether the NLRP3 inflammasome is also induced in tissues 
related to insulin resistance such as the liver, muscle or adipose tissue.  
 There are also evidences suggesting that autophagy, a pathway that 
allows the recycling of cellular constituents and facilitates cellular health 
under ER stress, may play an important role in obesity-induced insulin 
resistance [30], and recently it has been shown that activated mammalian 
target of rapamycin (mTOR) suppresses autophagy [31]. Recent results of 
our research group indicate that fructose markedly increases mTOR activity 
in the livers of 2- [14] and 8-week supplemented rats. Thus, it is plausible 
that chronic fructose administration would reduce autophagy via mTOR 
activation. Our preliminary unpublished results are in line with this 
hypothesis, as the ratio of active to inactive light chain 3 (LC3B), an 
indicator of autophagy, seems to be reduced in the livers of 8-week     
fructose-supplemented female rats (Figure 1). 
 It has been suggested that leptin, an adipokine mostly produced by white 
adipose cells, may also regulate autophagy [32]. A recent report showed that 
long-term (6 months) postnatal high fructose diet (60% in solid form) in 
Wistar rats did not affect plasma leptin levels, but decreased the mRNA 
expression of leptin receptors and autophagy-related genes in white adipose 
tissue, while increasing them in the liver [33]. Our results in rats supplemented 
with 10% liquid fructose for 8 weeks (non-published) show a significant              
1.8-fold increase in plasma leptin levels. However, when we express these 
results related to white adipose tissue weight, there is no difference between 
control and fructose-supplemented rats, suggesting that the increase of adipose 
tissue mass accounts for the observed hyperleptinemia.  
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b)
 
 
Figure 1. Differential effects of fructose in the livers of female Sprague-Dawley rats 
supplemented with 10% liquid fructose for a) 2 weeks and b) 8 weeks.  
 
 On the other hand, in our recent studies in C57/BL6 mice, we observed a 
2.3-fold, 5.5-fold and 7-fold increase in plasma leptin levels after 3 months 
of feeding a 15% liquid fructose diet, a western diet and western diet plus 
15% liquid fructose, respectively (non-published results). In this case, the 
increase of adipose tissue mass cannot explain the observed increases; 
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moreover, the mRNA leptin expression in adipose tissue was also increased 
by the three diets, following the same pattern of stepwise increase as plasma 
leptin levels.  
 
1.1.4. Progression to non-alcoholic steatohepatitis 
 
 The increase of de novo lipogenesis and liver steatosis induced by 
fructose feeding have been related to non-alcoholic fatty liver disease 
(NAFLD), which is considered the hepatic manifestation of the metabolic 
syndrome. Accumulation of triglycerides in the liver leads to oxidative stress 
and expression of proinflammatory cytokines, which results in progression 
from NAFLD to non-alcoholic steatohepatitis (NASH), characterized by 
inflammation, hepatocellular injury and hepatic fibrosis. Zhang et al. [34] 
showed that male Wistar rats fed a high fructose diet (32% fructose) 
developed hepatic steatosis at 4 weeks, but features of NASH (inflammatory 
cell infiltration and focal necrosis) appeared only at 8 weeks of fructose 
feeding. As oxidative stress plays a critical role in the progression of 
NAFLD to further stages of severity, Zhang et al. examined the role of the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), which 
mediates protection against oxidative stress and inflammation by increasing 
the hepatic expression of antioxidative enzymes. They showed that the 
amount of Nrf2 in rat hepatic nuclei was increased in rats fed the                     
high-fructose diet, a compensatory response which was not sufficient to 
overcome the imbalance state of oxidative stress associated to fructose 
feeding [34].  
 Inflammation also contributes to the progression of fructose-induced 
NAFLD into NASH. Zhang et al [34] showed higher plasma tumor necrosis 
factor alpha (TNFα) levels and increased nuclear factor kappa B (NF-κB) 
p65 in the nuclei of liver cells of high fructose fed male Wistar rats. Our own 
study in female Sprague Dawley rats fed fructose for the same length                 
(8 weeks) but to a lower proportion (10%) and supplemented in liquid 
instead of solid form, showed no clear signs of hepatic inflammation or 
necrosis [25]. On the contrary, in our study with C57/BL6 mice fed with a 
high fat diet, alone or combined with 15% liquid fructose, we observed a 
clear trend towards increase in several markers of hepatic inflammation, 
such as monocyte chemoattractant protein 1 (MCP-1), as well as in markers 
of hepatic fibrosis (collagen type 1 expression) [18]. 
 Tsuchiya et al. fed C57BL/6J mice a high-fat, high-fructose diet for 2 
to 16 weeks. As expected, they observed that the diet induced hepatic 
steatosis and insulin resistance, but the most interesting finding was that 2 
weeks before the onset of these alterations there was a significant increase in 
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hepatic non-heme iron content, and a decrease in antioxidant capacity in this 
organ [35]. The authors of this study suggest that the high-fat high-fructose 
diet, through causing hepatic iron overload, increases oxidative stress which 
later results in insulin resistance in the liver.   
   
1.2. Fructose effects on extrahepatic tissues 
 
1.2.1. Heart and cardiovascular system 
 
 In addition to effects on hepatic cells, fructose also causes disturbances 
in other tissues such as the heart and the vasculature. Thus, fructose feeding 
causes cardiac insulin resistance in ovariectomized female rats, shown by an 
impairment of Akt/endothelial nitric oxide synthase pathway [36]. The same 
research group reported that estradiol replacement in this animal model 
specifically suppresses these effects [37]. The results of this study suggest 
that the heart of female rats during the reproductive period is partially 
protected from the negative effects of excessive fructose intake. In fact, 
estrogen replacement has not always demonstrated a protective role against 
the detrimental cardiovascular effects of fructose. Thus, Koricanac et al. [38] 
found that estrogen enhanced the effects of fructose feeding in 
ovariectomized rats on the distribution and expression of CD36, the most 
important fatty acid transporter in cardiomyocytes. These effects would 
reinforce the negative effects of fructose by increasing cardiac fatty acid 
uptake and utilization, which is characteristic of cardiac insulin resistance 
[38].  
 The deleterious effects of an excess of fructose consumption on kidney, 
endothelium and heart have been associated with systemic hypertension 
through several mechanisms, among them the generation of uric acid [39].  
Hyperuricaemia increases oxidative stress and thus it may promote 
endothelial dysfunction. Uric acid may also raise systemic blood pressure by 
activating the renin-angiotensin system and by inhibiting nitric oxide 
synthase [40]. The role of uric acid has recently been demonstrated by           
Tapia et al [41]. They showed that blocking the enzyme uricase in rats 
enhances the alterations induced by fructose on systemic and glomerular 
blood pressure, as well as on other metabolic alterations (plasma glucose, 
hepatic triglyceride and oxidative stress).  
 Akar et al. examined the effects of a diet supplemented with 10-20% 
HFCS on vascular function in male Sprague-Dawley rats [42]. Consumption 
of 20% HFCS for 10 weeks increased blood pressure, impaired vascular 
relaxation to acetylcholine and increased the contractile response of aortas to 
phenylephrine and to angiotensin II. These effects were related to a 
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decreased endothelial nitric oxide synthase (eNOS) and sirtuin 1 (SIRT1) 
expression, together with an increased expression of NADPH oxidase, which 
caused an increase in superoxide production in the aorta of these animals. 
Resveratrol supplementation preserved vascular function and increased 
eNOS and SIRT1 expression in aortas [42]. We also performed some 
experiments in order to assess the effects of fructose on vascular reactivity, 
in collaboration with Dr. Rahimian’s group from the University of the 
Pacific (unpublished results). We observed reduced sensitivity to 
acetylcholine vasodilation in aortas exposed to high fructose concentrations 
(25 mM). Interestingly, the effect was more pronounced in aortas from male 
than from female rats. Gender differences in the response of rats to fructose 
have been already found in our previous in vivo studies [20]. Sexual 
dimorphism was also observed in mice deficient in the dual-specificity 
glucose and fructose transporter GLUT8. Thus, DeBosch et al. showed that 
female mice deficient in GLUT8 exhibited enhanced jejunal fructose uptake, 
which was related to exacerbated increases in blood pressure in response to 
high-fructose feeding compared to wild type mice [43]. On the contrary, 
male GLUT8-knockout mice exhibited lower systolic blood pressure both at 
baseline and after high-fructose feeding [44].  
 The renin-angiotensin system plays also an important role in fructose-
induced hypertension. Therefore, blocking angiotensin II receptors with 
losartan was shown to enhance renal cortical vascular responses to adrenergic 
stimuli, thus reducing fructose-induced hypertension in rats [45]. Similarly, the 
development of hypertension after 8 weeks of treatment with 60% dietary 
fructose was prevented by renin inhibition with aliskiren treatment [46].   
 Recently, it has been proposed that the immune system may also be 
related to cardiovascular alterations induced by fructose feeding. Thus, in a 
study performed by Leibowitz et al [47], male Sprague-Dawley rats fed a 
high-fructose diet (60% fructose) for 5 weeks induced a metabolic-like 
syndrome associated to vascular oxidative stress, inflammation and reduced 
IL-10 secretion from T regulatory lymphocytes (Treg). This suggests that 
despite the total number of Treg is not changed, their function is decreased 
leading to a reduction in the protective effect of these cells on the 
development of vascular injury. In this study, however, blood pressure was 
not altered, suggesting that the effect of Tregs is independent from blood 
pressure. The lack of effect of fructose feeding on blood pressure is 
attributed by the authors to a short fructose exposure. In fact, we found a 
slight increase in blood pressure in female rats after 8 weeks of 10% liquid 
fructose supplementation (unpublished results). 
 Insulin resistance and dyslipidemia have also been associated to a 
proatherogenic state, and therefore an excess of fructose consumption may 
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promote atherosclerosis development. There are only few studies addressing 
this problem, and the conclusions are not clear enough, as the animal model 
used to evaluate atherosclerosis development is a key factor. For example, 
feeding rats with a high fructose diet for 8 weeks facilitates the development 
of balloon injury-induced neointimal formation in carotid arteries [48]. 
However, the formation of atherosclerotic lesions is better assessed in mouse 
models such as the LDL receptor knock-out mouse (LDLR
-/-
), which 
develops atherosclerotic lesions similar to humans when challenged with 
high fat diets. We have studied the effect of fructose supplementation in 
drinking water (15% w/v), combined or not with a high fat diet, for 3 months 
in male LDLR
-/-
 mice. Our preliminary results indicate that supplementation 
with fructose induced atherosclerotic lesions in the aorta, which were much 
more extensive when fructose was combined with a high fat-diet. 
  
1.2.2. Fructose and adipose tissue 
 
 Fructose consumption has been linked to weight gain and obesity, but this 
is not always apparent in studies using rodents. For example, we have not 
detected any increase in weight gain in rats supplemented with liquid fructose 
for 14 days in our previous studies [19-21]. However, our more recent results 
in female rats receiving 10% liquid fructose for 8 weeks showed not only 
increased body weight, but also a significant increase in visceral adipose tissue 
mass (unpublished results). Alzamendi et al. also found an increase in adipose 
tissue mass in male Wistar rats treated with 10% liquid fructose for 3 weeks 
[49]. This effect was accompanied by a decrease in the number of cells per 
gram of adipose tissue, while cell diameter and volume were significantly 
increased by fructose. Similarly, Creszenzo et al. observed differences in 
adipocyte number and morphology in male rats fed 30% fructose in solid form 
for 8 weeks [50]. Thus, the number of intra-abdominal adipocytes was reduced 
due to an increase in their mean diameter, while the opposite (increased 
number but decreased adipocyte size) was found for the subcutaneous 
abdominal depot. Moreover, changes in size correlated with cell function and 
sensitivity to insulin action, therefore intra-abdominal fat tissue from            
fructose-fed rats displayed decreased phosphorylated Akt levels, suggesting 
reduced insulin signaling [50].  
 In vitro experiments in murine 3T3-L1 cells incubated in standard 
differentiation medium showed that addition of fructose increased 
adipogenesis and the expression of PPARγ, C/EBPα and the fructose 
transporter GLUT4 [51]. The authors were not able to tell whether fructose 
directly induced this transporter or the results were due to the earlier 
appearance of GLUT4 due to fructose-induced adipocyte differentiation. Our 
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own preliminary results in adipose tissue of rats supplemented for 8 weeks 
with 10% fructose shown an increase, although non-statistically significant, 
in the mRNA levels of GLUT4, and also of another transporter (GLUT5).    
 There are some evidences showing an increase in glucocorticoid levels 
in adipose tissue after high fructose feeding, probably due to the induction of 
the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) [52]. 
Velickovic et al. [53] studied the relationship between glucocorticoids and 
inflammatory mediators in rat adipose tissue and liver after 9 weeks on a diet 
containing a 10% fructose solution in drinking water. They observed that the 
level of corticosterone and of macrophage migration inhibitory factor (MIF) 
was significantly increased in the adipose tissue, but not in the liver of 
fructose-supplemented rats. The authors concluded that the glucocorticoid 
effects predominated over those of MIF, leading to attenuated NF-κB 
activation and unchanged TNFα expression. Similarly, our recent studies in 
the adipose tissue of rats supplemented with liquid fructose for 8 weeks 
showed no increase in inflammatory mediators, such as TNFα and monocyte 
chemotactic protein-1 (MCP-1). Interestingly, in adipose tissue samples of 
C57/BL6 mice fed a high fat diet, the addition of 15% liquid fructose 
produced a more marked increase in these inflammatory markers, specially 
MCP-1, as well as in markers of fibrosis (collagen type 1 expression), 
compared with animals fed only the high fat diet [18].  
  
1.2.3. Fructose and skeletal muscle  
  
 The importance of skeletal muscle in glucose homeostasis is highlighted 
by the fact that it is the major site of insulin-mediated glucose uptake in the 
postprandial state. Moreover, insulin resistance in skeletal muscle has been 
suggested to be one of the initial events in the establishment of type 2 
diabetes [54]. In a recent paper, Benetti et al. showed that feeding mice with 
15% HFCS for 30 weeks caused skeletal muscle insulin resistance (shown 
by the impaired phosphorylation of IRS-1, Akt, and GSK-3β) and 
inflammation (shown by enhanced expression of NF-κB, iNOS and ICAM-1), 
and these effects were attenuated by co-administration of a PPAR-δ agonist. 
The improvement in insulin resistance by the PPAR-δ agonist was attributed, 
at least in part, to an increase in the expression of GLUT-4 and GLUT-5 
transporters in skeletal muscle [55]. In male Wistar rats, 30% fructose 
feeding in solid form for 8 weeks did not cause any difference in the degree 
of Akt phosphorylation in skeletal muscle [56]. Neither did we find changes 
in phosphorylated Akt in female Sprague Dawley rats supplemented with 
10% liquid fructose for 8 weeks (non-published results). However, in both 
models there was a significant decrease when the phospho-Akt levels were 
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normalised to plasma insulin, suggesting that insulin action was impaired in 
skeletal muscle from fructose-fed rats. Interestingly, we observed a marked 
increase in the mRNA expression of GPR 119 in the skeletal muscle of our 
fructose-supplemented rats. GPR 199 is a G protein-coupled receptor which 
under activation impairs fatty acid and glucose oxidation by skeletal muscle, 
a condition that potentiates insulin resistance [57]. Thus, our preliminary 
results may be in accordance with fructose inducing insulin resistance in this 
tissue. 
 
2. Epidemiological and clinical studies 
 
 Since our last review published in 2012, there have been a number of 
epidemiological and clinical studies investigating the effects of high 
consumption of fructose or other sugar-sweetened beverages, in humans. 
One of these studies aimed to investigate the association between the 
consumption of sweetened beverages (juices and nectars, sugar-sweetened 
soft drinks and artificially sweetened soft drinks) and the incidence of type 2 
diabetes in a European cohort, the EPIC-InterAct study [58]. In this cohort, 
composed of men and women, only sugar-sweetened soft drink consumption 
was associated with an increase in the risk for type 2 diabetes after 
adjustment for body mass index. This suggests that obesity is not the only 
nor the main mediator of the association, and that other mechanisms of 
action might be involved, such as insulin resistance. In a similar study 
performed in a cohort composed only of women, similar results were 
obtained, although in this case not only for sugar sweetened beverages but 
also for artificial sweetened beverages [59]. However, none of these studies 
specifically assessed the effects of fructose consumption. Aeberli et al. [60] 
performed a randomized, cross-over trial in 9 healthy, normal-weight male 
volunteers (aged 21-25 years) who consumed four different sweetened 
beverages for 3 weeks each: medium fructose (MF) at 40 g/day, and high 
fructose (HF), high glucose (HG), and high sucrose (HS) each at 80 g/day. 
The results of the euglycemic-hyperinsulinemic clamps showed that the 
suppression of hepatic glucose production during insulin infusion was 
significantly lower after the HF intervention compared with HG, showing a 
decrease in hepatic insulin sensitivity after fructose consumption. In contrast, 
no significant differences among diets were seen in insulin-mediated glucose 
clearance, which is a parameter of whole-body (essentially muscle) insulin 
sensitivity. This suggests that impaired glucose tolerance by high fructose 
intake is explained by impaired suppression of hepatic glucose output rather 
than by muscle insulin resistance, at least with short-term high-fructose 
diets. However, the authors consider that it is possible that longer periods of 
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fructose administration could also alter muscle insulin sensitivity, possibly 
through a progressive deposition of ectopic fat in skeletal muscle. Another 
important finding was that all diets containing fructose (MF, HF, and HS), 
caused an elevation in total and LDL cholesterol, but not in triglyceride 
levels, compared with HG [60]. The lack of effect on plasma triglyceride 
may be attributed to the relatively low amount of fructose administered, 
compared to previous studies [61, 62]. 
 The above cited trials were performed in healthy individuals, but it has 
been claimed that the effects of fructose may be worse in subjects with 
obesity or other related metabolic diseases. Lewis et al. [63] performed a 
randomized controlled crossover study in overweight/obese subjects, who 
completed two 6 week dietary periods (separated by 4 week washout) 
consisting of two isocaloric diets that differed only in their sucrose content, 
the low-sucrose diet contributing 5% of total daily energy and the high-
sucrose diet 15% of total daily energy. There was no difference between 
both diets on insulin resistance measured by the hyperinsulinaemic-
euglycaemic glucose clamp, suggesting that there is no beneficial effect of a 
low-sucrose diet on peripheral glucose utilization. However, fasting plasma 
glucose, which is determined mainly by hepatic glucose production, was 
higher after the 15% sucrose diet compared to the 5% sucrose diet. 
Moreover, the results of the oral glucose tolerance test indicated higher 
insulin levels after the high sucrose diet at comparable levels of glycaemia 
[63]. These results would suggest that there is indeed some degree of hepatic 
insulin resistance after the higher sucrose diet. 
 In another study by Sevastianova et al. [64], overweight subjects were 
instructed to continue their normal diet and in addition to consume an extra 
1000 kcal/day with 98% of energy from carbohydrates (candy, pineapple 
juice, sugar-sweetened soft drinks, and/or carbohydrate-loading drink) for 3 
weeks, and thereafter they were placed on a hypocaloric diet for 6 months. 
During the carbohydrate overfeeding period, the study subjects gained a 2% 
of their body weight, which was correlated with a 27% increase in liver fat. 
The ratio of saturated to essential fatty acids in serum and VLDL 
triglycerides, taken as an index of de novo lipogenesis, was also significantly 
increased and correlated with liver fat content. All these changes are 
reversible by weight loss. The results suggest that an excess of simple sugar 
intake has a key role in the pathogenesis of NAFLD. 
 Children and youngsters constitute a population segment in which the 
prevalence of obesity is increasing, and this has coincided with a large 
increase in the consumption of sugar-sweetened beverages. Refreshing 
beverages enriched in fructose actually are the main source of dietary sugars 
in children. To explore the acute effects of fructose, Jin et al. performed a    
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2-day crossover feeding study in children with or without NAFLD [65]. 
Participants were randomly assigned to two nonconsecutive 24-h periods 
receiving three macronutrient-balanced meals with 33% of total estimated 
daily calories provided as an isocaloric, sugar-sweetened beverage 
containing either glucose or fructose, during a 24-h period.  The results 
showed that fructose caused a more marked increase in plasma triglyceride 
levels than glucose did, both in children with NAFLD and in those without 
NAFLD, but the increases were greater in children with NAFLD.  
 DeRuyter et al. [66] conducted a double-blind, randomized intervention 
study in 641 normal-weight children, who were randomly assigned to receive 
1 can per day of a noncaloric, artificially sweetened beverage or a                    
sugar-containing beverage (with 26 g of sucrose, providing 104 kcal). Both 
beverages tasted and looked essentially the same and were not labeled, to 
eliminate the effects of psychological cues and socially desirable behavior. 
The results of the study showed that weight gain, waist-to-height ratio, and fat 
mass were significantly higher in the group that received the sugar-sweetened 
beverage. To gain insight into the mechanisms explaining this difference, the 
same group recently conducted another similar study in children, and 
concluded that sugar-sweetened and sugar-free beverages produced similar 
satiety [67]. Therefore when children are given sugar-free instead of               
sugar-containing drinks they do not feel a need to eat more to compensate for 
the missing calories, so they gain less weight and accumulate less body fat. 
 Some clinical studies are intervention studies aimed to evaluate the effects 
of reducing fructose consumption. For example, Ebbeling et al [68] randomly 
assigned 224 overweight and obese adolescents who regularly consumed 
sugar-sweetened beverages to experimental and control groups. The 
experimental group received a 1-year intervention consisting of home delivery 
of noncaloric beverages to decrease consumption of sugar-sweetened 
beverages, with a follow-up for an additional year. At 1 year, increases in body 
mass index were significantly smaller in the intervention group than the 
control group, but changes were not sustained at 2 years.  
 
3. Conclusion 
 
 Excessive sugar consumption is beginning to be recognized as a huge public 
health problem worldwide. Some voices have risen about the need to promote 
policies to control the use of fructose [69], but others consider that public health 
policies to limit fructose in diet are premature because there is a lack of crucial 
studies demonstrating the toxicity of fructose [70,71]. Our studies performed in 
animal models, rats and mice receiving liquid fructose for short periods of time 
(2 weeks to 3 months) demonstrate that fructose exerts specific effects not 
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merely dependent on the caloric excess provided. In addition, our results suggest 
that the metabolic alterations induced by fructose are a dynamic continuum, and 
some effects that were apparent at short exposure times were not present after 
longer treatments. Taking into account that excessive fructose consumption in 
humans is usually a chronic dietary habit, our next challenge is to study the 
effects of fructose in these animal models after long-term supplementation.   
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